en · de · es · fr · pt
peptide-index.peptides9002.com › Guide › Peptide Identity And Structure — Field Notes

Peptide Identity And Structure — Field Notes

By Editorial Desk · published 2026-04-25 · last reviewed 2026-06-07 · Guide

The short version of mass spectrometry fits in a sentence. The long version — which is the one that helps — is below.

Reviewed 2026-06-07. Anything still debated is marked as such rather than presented as settled.

Peptide Identity and Structure

The compound was designed at the Institute of Molecular Genetics of the Russian Academy of Sciences during the 1980s and 1990s. The stated design goal was to retain the immunomodulatory and central nervous system activity attributed to tuftsin while improving resistance to enzymatic breakdown. Adding a proline-rich tail to the short parent peptide was a deliberate strategy, because proline residues restrict the conformations available to many peptidases. The same laboratory produced Semax, an ACTH fragment analog, and both compounds were developed in parallel as short, enzymatically stabilized peptides intended for intranasal use.

Selank is not a naturally occurring peptide and has no known endogenous counterpart in human physiology. Russian-language sources frequently call it TP-7, while English-language sources use the name Selank almost exclusively. Database indexing is uneven, partly because early reports appeared in regional journals that are not widely cataloged. Some summaries describe the material as a tuftsin analog and others as a synthetic heptapeptide; the labels overlap rather than conflict. Citing the primary sequence resolves ambiguity more reliably than the research or trade name alone.

Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, written TKPRPGP in one-letter notation. Its structure consists of the immunomodulatory tetrapeptide tuftsin, Thr-Lys-Pro-Arg, extended at the carboxyl terminus by a Pro-Gly-Pro segment. The molecular formula is commonly given as C33H57N11O9, corresponding to a monoisotopic mass near 751.4 Da and an average molecular mass near 751.9 Da. All seven residues are proteinogenic amino acids, and the molecule carries no modified side chains or non-natural linkages.

Background and Peptide Identity

Selank is a synthetic heptapeptide developed in Russia. Its sequence is Thr-Lys-Pro-Arg-Pro-Gly-Pro, a seven-residue chain built around the natural tetrapeptide tuftsin. Researchers at the Institute of Molecular Genetics of the Russian Academy of Sciences first described the compound in the mid-1990s. The design combined the tuftsin core with an added Pro-Gly-Pro tail, a modification intended to extend the molecule's stability in biological fluids. Published work on the peptide has appeared mainly in Russian-language journals.

Reported activity for Selank centers on anxiolytic and nootropic effects. Russian clinical reports describe use in anxiety and in cognitive or attention-related complaints. Most of this evidence comes from studies conducted by the same research groups that developed the peptide. Independent replication in other countries remains limited, and no major Western regulatory agency has approved the compound for any indication. The gap between local reports and external verification is a recurring point in discussions of the peptide.

Selank at a glance

PropertyValueNotes
Peptide sequenceThr-Lys-Pro-Arg-Pro-Gly-ProSeven residues; tuftsin plus a Pro-Gly-Pro tail
Molecular formulaC33H57N11O9Commonly reported value for the free peptide
Monoisotopic massRoughly 751.4 DaAverage molecular mass near 751.9 Da
AppearanceWhite to off-white powderTypically supplied as a lyophilized solid
Solubility classFreely soluble in waterAlso dissolves in saline and other polar solvents

Background and Molecular Identity

Development took place at the Institute of Molecular Genetics of the Russian Academy of Sciences, where a series of short peptides were designed in the 1980s and 1990s. Selank was selected from variants of tuftsin that showed resistance to plasma peptidases. Russian regulatory approval covers it as an anxiolytic agent given intranasally. Outside that market the compound is normally handled as a research chemical rather than a medicine, and no widely recognised international pharmacopoeial monograph exists. The name Selank is a coined trade designation rather than a systematic chemical name.

Enzymatic stability motivates the extra three residues at the carboxyl end. Native tuftsin is cleaved quickly by circulating aminopeptidases and carboxypeptidases, which limits its duration of action and its usefulness as a tool compound. Extending the chain with proline-rich segments is a common design tactic because proline constrains the backbone and slows proteolysis. The same Pro-Gly-Pro motif appears in other Russian-developed peptides of the era. Whether the full seven-residue chain is required for activity, or whether it acts mainly as a prodrug releasing tuftsin, remains unresolved.

Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. Its four N-terminal residues reproduce tuftsin, a tetrapeptide fragment of the immunoglobulin heavy chain, while the C-terminal Pro-Gly-Pro extension is a synthetic addition. The peptide has a molecular mass near 752 daltons and carries a net positive charge at physiological pH because of the arginine and lysine side chains. Published indexes list it under the name Selank and the sequence abbreviation TKPRPGP. Solid-phase peptide synthesis is the standard production route for research quantities.

Related pages on this site

Analytical Methods And Storage Stability

Quality assessment of Selank samples typically combines purity determination with identity confirmation and counter-ion analysis. Purity is usually reported as a percentage by chromatographic area, with values above 95 percent often quoted for research-grade material. Water content and residual solvents are checked in lyophilized batches because they affect both stability and accurate mass determination. A reported purity figure does not by itself establish that a sample is the intended sequence, so orthogonal methods are needed to rule out sequence isomers or truncation products.

Characterization of Selank in laboratory settings relies on standard peptide analytical techniques. Reverse-phase high-performance liquid chromatography separates the peptide from related impurities and degradation products, while mass spectrometry confirms molecular identity through accurate mass measurement. Amino acid analysis and peptide sequencing verify the primary structure when reference material is unavailable. Because Selank is a short chain, fragmentation-based analysis produces a diagnostic ion pattern that supports confident identification.

Peptide stability depends strongly on temperature, moisture, and pH. Lyophilized Selank is generally most stable when stored cold and dry, with freezer temperatures commonly used for long-term storage. In solution, the compound is susceptible to hydrolysis and to microbial growth if it is not handled aseptically. The C-terminal proline-rich extension appears to slow enzymatic cleavage relative to tuftsin, though quantitative degradation rates vary with the matrix and the conditions tested. Published stability data specific to Selank remain sparse.

Mechanism and Evidence Base

Clinical evidence comes mainly from small studies conducted in Russia, several of which were open-label or lacked robust blinding. Reported outcomes include lower anxiety scores, changes in attention measures, and effects on asthenic states following illness. Sample sizes are typically in the tens of participants, and independent replication outside the region is scarce. Reviews published in English generally note the limited methodological quality of the underlying trials. Whether the compound produces clinically meaningful effects under rigorous conditions remains unresolved.

Proposed mechanisms center on modulation of the GABA system, but no single molecular target has been confirmed. Rodent studies report changes in GABA-A receptor expression and in the turnover of serotonin, dopamine, and norepinephrine in several brain regions. Increases in brain-derived neurotrophic factor and its receptor have also been described after repeated administration. These findings come largely from animal models, and the degree to which they describe human neurochemistry remains an open question. The mechanism is best characterized as multi-system and not fully resolved.

Analytical Methods and Handling

Lyophilized Selank, the dry powder form, is generally stored frozen at minus 20 degrees Celsius or colder for long-term keeping. The solid is hygroscopic and should stay sealed, dry, and protected from light. Once dissolved, the peptide is less stable and is usually held refrigerated at 2 to 8 degrees Celsius for short periods. Repeated freezing and thawing is avoided because it can promote aggregation and loss of activity. Buffers and pH choice also affect how long a solution remains usable.

Solubility behavior is a practical concern for handling. Selank dissolves readily in water and in common aqueous buffers, which simplifies preparation of working solutions. The choice of solvent, ionic strength, and pH can influence aggregation over time, particularly at higher concentrations. Aqueous solutions are typically sterile-filtered before use. Because stability depends on several variables, storage and handling notes should be treated as general guidance rather than fixed rules, and specific values are best confirmed against a certificate of analysis for each batch.

Characterization of Selank in a laboratory setting relies on standard peptide methods. Reverse-phase high-performance liquid chromatography separates the target from related impurities and provides a purity figure, commonly reported as 95 percent or higher. Mass spectrometry, typically electrospray ionization or matrix-assisted laser desorption, confirms the molecular mass and helps detect truncation or modification. Amino acid analysis can verify composition when a sequence-level check is needed. These techniques together establish identity and purity for a given lot.

Reference notes

Somewhat unusually among theropods, T. rex had a very long cochlea. The length of the cochlea is often related to hearing acuity, or at least the importance of hearing in behavior, implying that hearing was a particularly important sense to tyrannosaurs. Specifically, data suggests that T. rex heard best in the low-frequency range, and that low-frequency sounds were an important part of tyrannosaur behavior. A 2017 study by Thomas Carr and colleagues found that the snout of tyrannosaurids was highly sensitive, based on a high number of small openings in the facial bones of the related Daspletosaurus that contained sensory neurons. The study speculated that tyrannosaurs might have used their sensitive snouts to measure the temperature of their nests and to gently pick up eggs and hatchlings, as seen in modern crocodilians. Another study published in 2021 further suggests that Tyrannosaurus had an acute sense of touch, based on neurovascular canals in the front of its jaws, which it could utilize to better detect and consume prey. The study, published by Kawabe and Hittori et al., suggests that Tyrannosaurus could also accurately sense slight differences in material and movement, allowing it to utilize different feeding strategies on different parts of its prey's carcasses depending on the situation. The sensitive neurovascular canals of Tyrannosaurus also likely were adapted to performing fine movements and behaviors such as nest building, parental care, and other social behavior such as intraspecific communication.

== External links == Ibogaine – Isomer Design Ibogaine – PsychonautWiki Ibogaine – Erowid Ibogaine Investigator`s Brochure Multidisciplinary Association for Psychedelic Studies (MAPS) The Big & Dandy Ibogaine/Iboga Thread – Bluelight Ibogaine – TiHKAL – Erowid Ibogaine – TiHKAL – Isomer Design Ibogaine: A Powerful Anti-Addictive Psychedelic – Tripsitter Ibogaine and Iboga: Traditional Use, Conservation, and Ethical Considerations – Double Blind Magazine

8 October – Conservative Party leader Kemi Badenoch delivers her keynote speech to the Conservative Party Conference on its final day. 9 October – Kensington Palace announces that Prince William will attend the COP30 conference in Brazil in November. Former prime minister Rishi Sunak takes up paid adviser roles with Microsoft and Anthropic, the earnings from which will be donated to the charity to tackle numeracy problems in the UK that he and his wife founded. Councillor Rowland O'Connor resigns as deputy leader of the Reform UK group on Cornwall Council. 10 October – Ash Regan resigns from the Alba Party in order to "focus" on her efforts to criminalise prostitution. Bristol City councillor Fabian Breckels is suspended from the Labour Party over an alleged racist comment posted on Facebook. 12 October – Starmer arrives in Egypt ahead of an international summit on the Gaza peace process where Downing Street says he will pay "particular tribute" to the US president, Donald Trump. 13 October – MI5 warns MPs they are being targeted in espionage operations by Russia, China and Iran. The Scottish National Party conference is held in Aberdeen. Councillor Rob Parsonage resigns as leader of the Reform UK group on Cornwall Council. 14 October – The Northern Ireland Troubles Bill, designed to replace the Northern Ireland Troubles (Legacy and Reconciliation) Act 2023, receives its first reading in the House of Commons.

Sources: en.wikipedia.org

Reference notes

=== Genetic testing === For inherited myopathies and muscular dystrophies, molecular genetic testing of peripheral blood, increasingly via next-generation sequencing panels, can confirm the diagnosis and often removes the need for muscle biopsy. Genetic testing is now recommended as a first-tier investigation in selected presentations such as unprovoked rhabdomyolysis, where it frequently identifies an underlying myopathy even when EMG and biopsy are unremarkable.

In the West, the decision was made through the 1957 Treaty of Rome to launch the first European Economic Community. It shared the Assembly and Court with the Coal and Steel Community, but set up parallel bodies for the Council and Commission. Based on the Spaak Report of 1956, it sought to break down all barriers to trade in a common market for goods, services, labour and capital, and prevent distortion of competition and regulate areas of common interest like agriculture, energy and transport. A separate treaty was signed for a European Atomic Energy Community to manage nuclear production. In 1961 the United Kingdom, Denmark, Ireland and Norway applied for membership only to be vetoed in 1963 by France's Charles de Gaulle. Spain also applied and was rejected as it was still led by the Franco dictatorship. The same year, the Court of Justice proclaimed that the Community constituted a "new legal order of international law". The Merger Treaty finally placed the ECSC and Euratom within the EEC. Shortly after, de Gaulle boycotted the commission, which he believed was pressing supranationalism too far. The Luxembourg compromise in 1966 agreed that France (or other countries) could veto issues of "very important national interest", particularly relating to the Common Agricultural Policy, instead of making decisions by "qualified majority". But after the May 1968 events in France and de Gaulle's resignation, the way was free for the United Kingdom, Ireland, and Denmark to join in 1973.

These "masculinized" genitalia are often found alongside other traits, such as female-dominated social groups, reduced sexual dimorphism that makes females the same size as males, and even ratios of sexes in adult populations. This phenomenon that has been dubbed the "lemur syndrome". A 2014 study of Eulemur masculinization proposed that behavioral and morphological masculinization in female Lemuriformes is an ancestral trait that likely emerged after their split from Lorisiformes.

== Society and culture == In 1966 in the U.S. and Canada, Jerry Lewis and the Muscular Dystrophy Association (MDA) began the annual Labor Day telecast The Jerry Lewis Telethon, significant in raising awareness of muscular dystrophy in North America. Some disability-rights advocates have criticized the telethon for portraying victims of the disease as deserving pity rather than respect. On December 18, 2001, the MD CARE Act was signed into law in the United States. The law amends the Public Health Service Act to provide research for the various muscular dystrophies and established the Muscular Dystrophy Coordinating Committee to help focus research efforts through a coherent research strategy.

Sources: en.wikipedia.org

Frequently asked questions

What is the primary sequence of Selank?

The sequence is Thr-Lys-Pro-Arg-Pro-Gly-Pro, written TKPRPGP in one-letter code. It combines the tetrapeptide tuftsin with a carboxyl-terminal Pro-Gly-Pro extension. This full sequence identifies the molecule more precisely than the research name.

Is Selank found naturally in the body?

No peptide with this exact sequence has been identified as an endogenous substance. It is a laboratory-designed analog of tuftsin, a naturally occurring immunomodulatory tetrapeptide. The Pro-Gly-Pro extension has no known natural source.

Why does the peptide contain three proline residues?

Proline introduces conformational constraints that make a peptide less accessible to common peptidases. This is a standard stabilization strategy in peptide design. The added residues also increase the distance between the active tuftsin portion and typical cleavage sites.

What type of molecule is Selank?

Selank is a synthetic peptide made of seven amino acids. It is modeled on tuftsin, a natural tetrapeptide, with an added three-residue tail. It is not a small-molecule drug.

Network